- Home
- SB vs BBNX Comparison
SB vs BBNX Comparison
Compare SB & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SB | BBNX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Monaco | United States |
| Employees | N/A | 423 |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 591.5M | 493.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SB | BBNX |
|---|---|---|
| Price | $6.25 | $10.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $6.00 | ★ $26.22 |
| AVG Volume (30 Days) | 758.4K | ★ 1.1M |
| Earning Date | 02-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.47 | $34.99 |
| Revenue Next Year | $3.61 | $34.47 |
| P/E Ratio | $16.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $8.89 |
| 52 Week High | $6.68 | $32.71 |
Technical Indicators
Market Signals| Indicator | SB | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 32.80 |
| Support Level | $4.16 | N/A |
| Resistance Level | $6.68 | $15.53 |
| Average True Range (ATR) | 0.19 | 0.64 |
| MACD | -0.06 | 0.19 |
| Stochastic Oscillator | 47.27 | 28.83 |
Price Performance
Historical ComparisonAbout SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.